A chimeric antigen receptor that specifically binds to the CD300C antigen or its receptor

A chimeric antigen receptor targeting CD300c antigen enhances cancer treatment by specifically binding to cancer cells, suppressing proliferation and metastasis, and overcoming resistance, providing a broad therapeutic benefit with reduced side effects.

JP7578869B2Active Publication Date: 2024-11-07CENTRICSBIO INC

Patent Information

Application Number
JP2022532160
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-11-27
Filing Date
2020-11-30
Publication Date
2024-11-07
Estimated Expiration
2040-11-30

AI Technical Summary

Technical Problem

Current cancer treatments, including targeted anticancer drugs and immune checkpoint inhibitors, face limitations such as high side effects, resistance development, and limited effectiveness across various cancer types, necessitating the development of new immune-based therapies.

Method used

A chimeric antigen receptor (CAR) specifically designed to bind to the CD300c antigen or its receptor, comprising components like antibodies, single domain antibodies, and intracellular domains, is introduced into immune cells to enhance cancer treatment efficacy.

Benefits of technology

The CAR effectively targets and suppresses cancer cell proliferation, metastasis, and resistance, offering a broad therapeutic benefit across various cancer types with reduced side effects by activating T cells and inhibiting CD300c protein production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578869000002
    Figure 0007578869000002
  • Figure 0007578869000003
    Figure 0007578869000003
  • Figure 0007578869000004
    Figure 0007578869000004
Patent Text Reader

Abstract

The present invention relates to a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, and immune cells expressing the same. The chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor according to the present invention not only specifically recognizes cancer cells expressing the CD300c antigen or CD300c receptor and effectively suppresses cancer growth, metastasis, etc. directly, but also activates T cells in the body through CD300c inhibition, thereby reducing side effects and increasing the therapeutic effect of cancer, and is therefore expected to be effectively used as an immunotherapeutic agent for various cancers.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, an immune cell expressing the same, and uses thereof. [Background technology]

[0002] Cancer is one of the most important causes of death in modern society. It is a disease that occurs when normal cells change due to genetic mutations caused by various factors, and it is a malignant type of tumor that does not follow the differentiation, proliferation, and growth patterns of normal cells. Cancer is characterized as "uncontrolled cell growth," and this abnormal cell growth forms a cell mass called a tumor, which infiltrates the surrounding tissues and, in severe cases, metastasizes to other organs in the body. Cancer is an intractable chronic disease that, even if treated with surgery, radiation, and drug therapy, does not lead to a fundamental cure in many cases, causing pain to patients and ultimately leading to death. In particular, the global cancer incidence rate has been increasing by more than 5% annually due to the increase in the elderly population and the worsening environment, and according to a WHO report, it is estimated that the number of people with cancer will increase to 30 million within the next 25 years, and 20 million of them will die from cancer.

[0003] Cancer drug therapy, i.e., anticancer drugs, are generally cytotoxic compounds that attack and kill cancer cells, but they cause severe side effects because they damage not only cancer cells but also normal cells. Therefore, targeted anticancer drugs have been developed to reduce side effects. However, although such targeted anticancer drugs have been able to reduce side effects, they have a high probability of developing resistance, which is a limitation. Therefore, there has been a recent trend of increasing interest in immune anticancer drugs that use the body's immune system to reduce problems caused by toxicity and resistance. As an example of such immune anticancer drugs, immune checkpoint inhibitors have been developed that specifically bind to PD-L1 on the surface of cancer cells, inhibit the binding of T cells to PD-1, and activate T cells to attack cancer cells. However, even with such immune checkpoint inhibitors, there is a limited number of cancers for which they are effective, so there is a strong demand for the development of new immune checkpoint inhibitors that show the same therapeutic effect on various cancers (Korea Patent Publication No. 10-2016-0016725).

[0004] Meanwhile, chimeric antigen receptors (CARs) are artificial receptors designed to transmit antigen specificity to T cells, and are composed of antigen-specific components, transmembrane components, intracellular components, etc. that are selected to activate T cells and provide specific immunity. Recently, active research is being conducted on cancer immunotherapy using cells that have been introduced with genes encoding such chimeric antigen receptors, that is, methods of treating cancer through a therapy in which T cells are collected from a patient, genes encoding chimeric antigen receptors are introduced into such T cells, amplified, and then transferred back to the patient. Summary of the Invention [Problem to be solved by the invention]

[0005] The present invention has been devised to solve the problems in the conventional technology as described above, and aims to provide a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, an immune cell expressing the same, and a composition for preventing or treating cancer using the same.

[0006] However, the technical problem that the present invention aims to achieve is not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those having ordinary skill in the art from the following description. [Means for solving the problem]

[0007] The present invention provides chimeric antigen receptors that specifically bind to the CD300c antigen or its receptor.

[0008] In one embodiment of the present invention, the chimeric antigen receptor preferably comprises an antibody, single domain antibody, single chain variable fragment (scFv), etc., that specifically binds to the CD300c antigen, or comprises a CD300c antigen, thereby being capable of specifically recognizing and binding to the CD300c antigen or its receptor. The CD300c antigen may comprise the entire sequence of the CD300c antigen, or may comprise only the extracellular domain (ECD) of the CD300c antigen sequence, in order to bind to the receptor. The extracellular domain sequence of the CD300c antigen may comprise the amino acid sequence shown in SEQ ID NO: 14, and preferably comprises an amino acid sequence having a sequence homology of 90% or more, more preferably 95% or more, and most preferably 98% or more with SEQ ID NO: 14. In addition, the antibody, single domain antibody, single chain variable region fragment, etc., may contain an amino acid sequence represented by SEQ ID NO: 4, 6, 8, 10, or 12 in order to bind to the CD300c antigen, and may preferably contain an amino acid sequence having 90% or more, more preferably 95% or more, and most preferably 98% or more sequence homology with SEQ ID NO: 4, 6, 8, 10, or 12. The "sequence homology percentage" for an amino acid sequence is determined by comparing a comparison region with an optimally aligned sequence, and a portion of the amino acid sequence in the comparison region may further contain additions or deletions (i.e., gaps) compared to a reference sequence (without additions or deletions) for the optimal sequence of the sequence. However, the sequence is not limited thereto as long as it can specifically bind to the CD300c antigen or its receptor.

[0009] In another embodiment of the present invention, the chimeric antigen receptor may further include, preferably, a signal peptide, a GS linker, a transmembrane domain, an intracytoplasmic domain, etc., but is not limited thereto as long as it is a commonly known component of a chimeric antigen receptor.

[0010] In yet another specific example of the present invention, preferably, the signal peptide may include a CD8α signal peptide sequence, the transmembrane region may include sequences such as a CD8 hinge of cluster of differentiation 8, a CD28 transmembrane domain, and the intracytoplasmic region may include sequences such as a CD28 intracellular domain, a CD3ζ intracellular domain, and the like.

[0011] In yet another embodiment of the present invention, the chimeric antigen receptor may be used in the treatment of cancers expressing the CD300c antigen on their surface by specifically recognizing and / or binding to the CD300c antigen or its receptor.

[0012] The present invention also provides a recombinant vector expressing the chimeric antigen receptor.

[0013] The present invention also provides an immune cell transformed with the recombinant vector.

[0014] In one embodiment of the present invention, the immune cells are preferably monocytes, macrophages, T cells, natural killer cells (NK cells), dendritic cells, etc., but are not limited thereto as long as they are immune cells used in cancer treatment.

[0015] The present invention also provides a pharmaceutical composition for preventing or treating cancer expressing the CD300c antigen or CD300c receptor, comprising the immune cells as an active ingredient.

[0016] In one embodiment of the present invention, the cancer is colorectal cancer, rectal cancer, colon cancer, thyroid cancer, oral cancer, pharyngeal cancer, laryngeal cancer, cervical cancer, brain cancer, lung cancer, ovarian cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, prostate cancer, skin cancer, tongue cancer, breast cancer, uterine cancer, stomach cancer, bone cancer, blood cancer, etc., but is not limited to these, as long as the cancer type expresses CD300c antigen or CD300c receptor on its surface.

[0017] In another embodiment of the present invention, the pharmaceutical composition may further include other existing anticancer drugs, preferably the toxin rubicin, cisplatin, gemcitabine, oxaliplatin, 5-FU, cetuximab, panitumumab, nimotuzumab, necitumumab, cancer antigens, anticancer viruses, etc., but are not limited thereto as long as they are substances currently used as anticancer drugs. The cancer antigen is a cancer vaccine specific to a carcinoma, preferably NY-ESO-1 as a bladder cancer specific cancer antigen, HER2 as a breast cancer specific cancer antigen, CEA as a colon cancer specific cancer antigen, VEGFR1, VEGFR2, etc., but are not limited thereto as long as they are types of cancer antigens known as cancer vaccines. Examples of anticancer viruses include ImmuRigic and Pexa-Vec, but are not limited thereto as long as they are known anticancer viruses. The anti-cancer drug may be preferably co-administered, may be contained in the immune cells of the present invention, may be bound to a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, or may be contained in a carrier of the anti-cancer drug, but is not limited thereto.

[0018] In yet another embodiment of the present invention, the pharmaceutical composition is characterized by suppressing the proliferation, survival, metastasis, recurrence, anticancer drug resistance, etc. of cancer or cancer stem cells, but is not limited thereto as long as the effect is produced by the pharmaceutical composition of the present invention.

[0019] The present invention also provides a method for treating cancer, comprising the step of administering to an individual a composition comprising, as an active ingredient, immune cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor.

[0020] The present invention also provides a use of a composition comprising, as an active ingredient, an immune cell expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor for the prevention or treatment of cancer.

[0021] The present invention also provides the use of immune cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor for the production of a drug for cancer treatment. Effect of the Invention

[0022] The chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor according to the present invention can be effectively used as an immunotherapeutic agent for various cancers by activating T cells and suppressing the proliferation of cancer cells by specifically binding to the CD300c antigen or its receptor expressed on the surface of various cancers with high binding strength. In addition, it has been confirmed that by using immune cells expressing the chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor according to the present invention, the immune cells themselves can have a therapeutic effect, and by suppressing the production of CD300c protein through the chimeric antigen receptor, T cells can be activated and the proliferation of cancer cells can be suppressed, thereby effectively suppressing the growth, development, metastasis, etc. of cancer cells. In addition, when immune cells expressing the chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor according to the present invention are treated with cancer cells that exhibit the ability to resist cell death, it is expected to significantly weaken such ability of the cancer cells and show excellent efficacy in preventing cancer recurrence. [Brief description of the drawings]

[0023] [Figure 1]1 is a schematic diagram showing gene configuration for constructing a chimeric antigen receptor that specifically binds to CD300c antigen or its receptor in accordance with one embodiment of the present invention. [Diagram 2] 1 is a diagram showing a vector map for constructing a chimeric antigen receptor that specifically binds to CD300c antigen or its receptor, in accordance with one embodiment of the present invention. [Diagram 3] FIG. 1 shows the results of Western blotting of a Jurkat cell line expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, according to one embodiment of the present invention. [Figure 4] 1 is a diagram showing the results of confirming the anti-cancer effect of a Jurkat cell line expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, in accordance with one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Immune cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor of the present invention can effectively suppress the growth of cancer cells and the progression of cancer by effectively inhibiting the CD300c mechanism by specifically binding to the CD300c antigen or its receptor on the surface of cancer cells, and therefore can be effectively used in the treatment of various cancers that express the CD300c antigen or CD300c receptor on their surface.

[0025] As used herein, the term "antibody" refers to an immunoglobulin molecule immunologically reactive with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, and functional fragments thereof. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies) and heterologous antibodies (e.g., bispecific antibodies). Among these, monoclonal antibodies are antibodies that exhibit a single binding specificity and affinity for a single antigenic site (epitope). Unlike polyclonal antibodies, which include antibodies that exhibit specificity for different epitopes, monoclonal antibodies exhibit binding specificity and affinity only for a single epitope on an antigen, and therefore are easy to quality control as a therapeutic agent. In particular, the anti-CD300c monoclonal antibody of the present invention not only exhibits anti-cancer activity by itself by specifically binding to cancer cells expressing CD300c, but also maximizes cancer cell-dependent anti-cancer activity by stimulating immune cells. The antibody comprises a heavy chain and / or light chain variable region, and the variable region comprises a portion that forms the antigen-binding site of the antibody molecule as a primary structure. The antibody of the present invention may be composed of a fragment containing the variable region. Preferably, the variable region may be replaced with a soluble receptor for CD300c, but is not limited thereto as long as it shows the same effect as the anti-CD300c monoclonal antibody of the present invention.

[0026] As used herein, the term "single domain antibody" refers to an antibody specific to the CD300c antigen, in which the CDR is part of a single domain polypeptide, and may generally be an antibody constructed using only two heavy chains and an antigen-binding site, but may also include antibodies that do not naturally have a light chain, single domain antibodies derived from conventional four-chain antibodies, engineered antibodies, and single domain scaffolds other than those derived from antibodies.

[0027] As used herein, the term "single-chain variable fragment (scFv)" refers to a protein in which the variable regions of the light and heavy chains of an antibody are linked by a linker consisting of a peptide sequence of about 15 amino acids, and the order of the linker may be either light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region, and the scFv has the same or similar antigen specificity as the original antibody. The linking site is a hydrophilic flexible peptide chain (GS linker) consisting mainly of glycine and serine, and the 15 amino acid sequence "(Gly-Gly-Gly-Gly-Ser)3" or a sequence similar thereto is mainly used. The antibody refers to an immunoglobulin molecule immunologically reactive with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, and all of their functional fragments. The term also includes forms produced by genetic engineering, such as chimeric antibodies (e.g., humanized murine antibodies) and heterologous antibodies (e.g., bispecific antibodies). Among them, monoclonal antibodies are antibodies that exhibit a single binding specificity and affinity for a single antigenic site (epitope). Unlike polyclonal antibodies, which include antibodies that exhibit specificity for different epitopes, monoclonal antibodies exhibit binding specificity and affinity only for a single epitope on an antigen, and therefore are easy to quality control as therapeutic agents. In particular, the anti-CD300c monoclonal antibody of the present invention not only exhibits anti-cancer activity by itself by specifically binding to cancer cells expressing CD300c, but also maximizes cancer cell-dependent anti-cancer activity by stimulating immune cells. The antibody includes variable regions of heavy chains and / or light chains, and the variable regions include a portion that forms an antigen-binding site of an antibody molecule as a primary structure, and the antibody of the present invention may be composed of a fragment including the variable regions.

[0028] As used herein, the term "prevention" refers to any action of suppressing or delaying the onset of a disease such as cancer by administering the pharmaceutical composition of the present invention.

[0029] As used herein, the term "treatment" refers to any action that improves or favorably alters symptoms of cancer or the like by administration of the pharmaceutical composition of the present invention.

[0030] As used herein, the term "individual" refers to a subject to which the pharmaceutical composition of the present invention can be administered, and there is no limitation to the subject.

[0031] In the present specification, the term "pharmaceutical composition" may be in the form of a capsule, tablet, granule, injection, ointment, powder, or drink, and the pharmaceutical composition may be intended for humans. The pharmaceutical composition may be formulated and used in the form of oral dosage forms such as powder, granule, capsule, tablet, aqueous suspension, external preparation, suppository, and sterile injection solution, but is not limited thereto, by a conventional method. The pharmaceutical composition of the present invention may contain a pharmaceutical acceptable carrier. The pharmaceutical acceptable carrier may be a binder, lubricant, disintegrant, excipient, solubilizer, dispersant, stabilizer, suspending agent, dye, flavor, etc., when administered orally, and may be used in the form of a buffer, preservative, soothing agent, solubilizer, isotonicity agent, stabilizer, etc., when administered locally. A base, excipient, lubricant, preservative, etc. may be used in the form of a topical administration. The dosage form of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with the pharmaceutical acceptable carrier as described above. For example, for oral administration, the compound may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injection, the compound may be prepared in the form of unit dose ampoules or multiple doses. In addition, the compound may be formulated as a solution, suspension, tablet, capsule, sustained release formulation, etc.

[0032] On the other hand, examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc. Also, fillers, anti-agglomerating agents, lubricants, wetting agents, flavors, emulsifiers, preservatives, etc. may be further included.

[0033] The routes of administration of the pharmaceutical compositions of the present invention include, but are not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, percutaneous, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal. Oral or parenteral administration is preferred. The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intradural, intralesional, and intracranial injection or infusion techniques. The pharmaceutical compositions of the present invention may also be administered in the form of suppositories for rectal administration.

[0034] The pharmaceutical composition of the present invention may vary depending on various factors including the activity of the specific compound used, age, body weight, general health, sex, dietary requirements, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated. The dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route, and period, but may be appropriately selected by those skilled in the art and may be administered at 0.0001 to 500 mg / kg or 0.001 to 500 mg / kg per day. The dosage may be administered once a day or in several divided doses. The dosage does not limit the scope of the present invention in any case. The pharmaceutical composition of the present invention may be formulated into pills, sugar-coated tablets, capsules, liquids, gels, syrups, slurries, and suspensions.

[0035] The following examples are presented below to aid in understanding the present invention, but they are merely provided to facilitate understanding of the present invention and are not intended to limit the scope of the present invention.

[0036] <Example> Example 1: Preparation of a chimeric antigen receptor expression vector that specifically binds to the CD300c antigen or its receptor In order to prepare a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, a CD8α signal peptide (DNA sequence: SEQ ID NO: 1) containing the amino acid sequence of SEQ ID NO: 2, which enables the synthesized protein to pass through the cell membrane and move to a precise location, anti-CD300c single chain variable fragments (aCD300c scFvs; DNA sequences are SEQ ID NOs: 3, 5, 7, 9, and 11) of CK1, CL6, CL7, CL10, and SL18 containing the amino acid sequences of SEQ ID NOs: 4, 6, 8, 10, and 12 that specifically bind to the CD300c antigen or its receptor, or a CD300c ECD (extracellular domain) antigen (DNA sequence: SEQ ID NO: 13) containing the amino acid sequence of SEQ ID NO: 14, a GS linker (DNA sequence: SEQ ID NO: 15) containing the amino acid sequence of SEQ ID NO: 16, and a CD8 hinge of cluster of differentiation containing the amino acid sequence of SEQ ID NO: 18 as a transmembrane domain, were inserted into a pLVX-Puro vector (Addgene). 8, DNA sequence is SEQ ID NO: 17), CD28 transmembrane domain containing the amino acid sequence of SEQ ID NO: 20 (DNA sequence is SEQ ID NO: 19), CD28 intracellular domain containing the amino acid sequence of SEQ ID NO: 22 as an intracytoplasmic domain for macrophage activation signal transduction (DNA sequence is SEQ ID NO: 21), and CD3ζ intracellular domain containing the amino acid sequence of SEQ ID NO: 24 (DNA sequence is SEQ ID NO: 23) were inserted in this order to prepare a chimeric antigen receptor expression vector (pLVX-Puro / aCD300c scFv or pLVX-Puro / CD300c ECD-CAR) that specifically binds to the CD300c antigen or its receptor. The combination of gene and protein sequences of each vector prepared is shown in Table 1. A schematic diagram of the gene sequence is shown in FIG. 1, and an example of the constructed vector map is shown in FIG. 2.

[0037] [Table 1]

[0038] Example 2. Production of recombinant lentivirus for expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor The HEK293T cell line (ATCC) required for the production of recombinant lentivirus for expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor was prepared as follows. The complete medium used for cell culture was prepared by adding heat-treated fetal bovine serum (FBS) to fresh DMEM medium (Gibco) to a concentration of 10%, adding 1X Penicillin-Streptomycin (Gibco), mixing uniformly by inversion, and preheating to 37°C. The HEK293T cell line was used by transferring frozen cell stocks to a 37°C water bath immediately before use, thawing for 2-3 minutes, inoculating them into 30mL of complete medium, and culturing them in a 5% CO2 incubator at 37°C. When the cell saturation reached 80% or more, the cells were subcultured and maintained. For lentivirus transfection, the HEK293T cell line was cultured at 1-2 x 10 6 The cells were inoculated into 10 mL of complete medium at a concentration of 10,000,000 cells and cultured for 16 hours before lentiviral transfection.

[0039] Lentivirus transduction for expression of a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor was performed using the Lenti-X TM The Expression System (Takara) kit was used. Sterile water (Invitrogen) was added to 7 μg of pLVX-Puro / aCD300C scFv or pLVX-Puro / CD300c ECD-CAR expression vector prepared in the same manner as in Example 1 to make a total volume of 600 μL, and then the Lenti-X TMThe nanoparticle complex solution was prepared by mixing it in a Lenti-X Packaging Single Shots tube in the Expression System. The nanoparticle complex solution, which had been reacted at room temperature for 10 minutes, was then added dropwise to the HEK293T cells prepared in advance and mixed by shaking side to side. After culturing for 4 hours in an incubator, an additional 6 mL of fresh complete medium was added and the cells were cultured for 48 hours. After culturing, the supernatant was collected and centrifuged to remove cell debris, then filtered through a 0.45 μm filter and stored at -80°C until use.

[0040] 20 μL of the lentivirus supernatant was transferred to Lenti-X TM Add to the GoStix cassette sample well (S) in the Expression System, drop 3 drops of Chase solution into the sample well, and react at room temperature for 10 minutes. Then, 5x10 5 It was confirmed that a recombinant lentivirus with an effective dose of IFU / mL or more was obtained.

[0041] As a result, it was confirmed that recombinant lentiviruses expressing chimeric antigen receptors that specifically bind to the CD300c antigen or its receptor were produced. It was confirmed that the produced lentiviruses express chimeric antigen receptors containing the amino acid sequences of SEQ ID NOs: 4, 6, 8, 10, 12, and 14, respectively.

[0042] Example 3: Production of Jurkat cells expressing chimeric antigen receptors that specifically bind to the CD300c antigen or its receptor To produce Jurkat cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, the recombinant lentivirus produced in the same manner as in Example 2 was transfected into a Jurkat cell line. More specifically, the recombinant lentivirus was inoculated at 0.1 to 10 MOI into a complete medium supplemented with 8 μg / mL polybrene (Merk) and mixed uniformly by inverting. The mixture was then added to Jurkat cell lines prepared in 6-well plates in 1 mL portions, centrifuged at 1,800 rpm for 45 to 90 minutes, and cultured in a 37°C, 5% CO2 incubator for 24 hours. After 24 hours, 5X10 5 The cells were subcultured at a concentration of 1000 cells / mL.

[0043] To confirm whether the chimeric antigen receptor that specifically binds to CD300c antigen or its receptor is normally expressed in the transfected Jurkat cell line, the total protein of the cultured Jurkat cells was obtained using PRO-PREP solution (iNtRON). The concentration of the obtained protein was measured using a microBCA protein assay kit (Thermofisher), and then Western blotting was performed using the same amount of protein. More specifically, the same amount of protein was electrophoresed on SDS-PAGE (Invitrogen), and the electrophoresed protein was transferred to a nitrocellulose membrane (Invitrogen). The nitrocellulose membrane to which the protein was bound was blocked using a 5% skim milk (BD) solution to block nonspecific antibody reactions, and anti-CD3 antibody and anti-GAPDH antibody (Cell Signaling Technologies, USA) were diluted to a concentration of 1:1,000 using 5% skim milk as primary antibodies, which were then treated and reacted with the nitrocellulose membrane, after which unbound antibodies were removed. The secondary antibody was horseradish peroxidase (HRP)-conjugated secondary antibody (Cell Signaling Technologies) diluted at a concentration of 1:2,000. After inducing a color reaction by treating with ECL solution (Thermofisher), the amount of protein was quantified using a luminescent image analyzer iBright1500 (Invitrogen). The results of Western blotting are shown in Figure 3.

[0044] As shown in Figure 3, the CD3ζ intracellular domain bound to the anti-CD3 antibody was identified, and it was confirmed that a Jurkat cell line expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor was produced.

[0045] Additionally, the expression level of the chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor was confirmed using a flow cytometer (FACS). More specifically, Jurkat cell lines were treated with PE-fused anti-IgG antibody (Jackson immunoresearch), incubated at 4°C for 30 minutes, and then confirmed using a flow cytometer.

[0046] Flow cytometry analysis confirmed that a Jurkat cell line expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor had been produced.

[0047] Example 4: Confirmation of CD300c expression in cancer cells To evaluate whether CD300c is expressed in various cancer cells, various human solid cancer cell lines were cultured and CD300c expression was evaluated at the mRNA and protein levels. More specifically, human lung cancer cell line A549, human breast cancer cell line MDA-MB-231, and mouse colon cancer cell line CT26 were cultured, and each cell was fixed with 4% formaldehyde and blocked with 5% normal goat serum. Then, after treating and reacting with 1μg of anti-CD300c antibody, the cells were stained with FITC-labeled anti-rabbit IgG antibody. Fluorescently labeled cells were then identified using a flow cytometer (FACS).

[0048] As a result, it was confirmed that various cancer cells, including colon cancer, lung cancer, and breast cancer, have the CD300c antigen on their cell surfaces.

[0049] Example 5: Anti-cancer effect of Jurkat cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor To confirm the anti-cancer effect of Jurkat cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, the cancer cell killing effect was confirmed using the A549 cell line. More specifically, the A549 cell line was cultured at 1x10 5The cells were seeded at a concentration of 1000 cells / mL. Jurkat cells expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, which were prepared by the same method as described in Example 3, were treated with the cancer cells at a concentration of 20:1 and co-cultured. Jurkat cells that were not transfected with lentivirus were used as a control. After co-culture for 24 hours, the co-cultured Jurkat cell line was removed from each well and reacted with CCK-8 (Dojindo) for 1 hour, and then the OD 450nm The degree of cancer cell death was confirmed by measuring the absorbance at 100 nm and the results are shown in Figure 4.

[0050] As shown in Figure 4, it was confirmed that the Jurkat cell line expressing a chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor exhibited an anti-cancer effect against the A549 cell line, and exhibited a higher anti-cancer effect than the Jurkat cell line that was not transfected with the lentivirus.

[0051] From the above results, it was confirmed that the use of immune cell lines expressing chimeric antigen receptors that specifically bind to CD300c antigen or its receptor can increase the efficacy of cancer treatment using immune cell lines and effectively treat cancer. In addition, it was confirmed that side effects can be reduced and therapeutic efficacy can be maximized because it specifically reacts only to cancer cells expressing CD300c antigen on their surface.

[0052] The above description of the present invention is for illustrative purposes only, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical concept or essential features of the present invention. Therefore, the above-described embodiments should be understood to be illustrative and not restrictive in all respects. Industrial Applicability

[0053] The chimeric antigen receptor of the present invention that specifically binds to the CD300c antigen or its receptor specifically binds to the CD300c antigen or its receptor, and therefore can be used to treat all cancers that secrete the CD300c antigen. Not only can it reduce side effects by activating T cells and the like in the body through the inhibition of CD300c, but it can also increase the therapeutic effect of cancer, and thus can be effectively used in the immunotherapy of various cancers. The present invention includes the following aspects. <1> A chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor, The chimeric antigen receptor comprises at least one selected from the group consisting of an antibody that specifically binds to a CD300c antigen or its receptor, a single domain antibody, a single-chain variable region fragment, and an antigen. <2> The chimeric antigen receptor is characterized in that it comprises an amino acid sequence represented by SEQ ID NO: 4, 6, 8, 10, 12 or 14. <1> The chimeric antigen receptor described in. <3> The chimeric antigen receptor further comprises a signal peptide, a GS linker, a transmembrane domain, and an intracytoplasmic domain. <1> The chimeric antigen receptor described in. <4> The signal peptide is a CD8α signal peptide. <3> The chimeric antigen receptor described in. <5> The transmembrane domain is a CD8 hinge of cluster of differentiation 8 and a CD28 transmembrane domain, <3> The chimeric antigen receptor described in. <6> The cytoplasmic domain is a CD28 intracellular domain and a CD3ζ intracellular domain, <3> The chimeric antigen receptor described in. <7> The chimeric antigen receptor is characterized in that it is used for the treatment of cancer expressing CD300c antigen or CD300c receptor. <1> The chimeric antigen receptor described in. <8> <1> ~ <7> A recombinant vector expressing the chimeric antigen receptor described in any one of claims 1 to 4. <9> <8> Immune cells transformed with the recombinant vector described in. <10> The immune cells include monocytes, macrophages, T cells, and natural killer cells. The cell is at least one selected from the group consisting of NK cells (killer cells; NK cells) and dendritic cells. <9> The immune cell according to claim 1. <11> <9> A pharmaceutical composition for preventing or treating cancer expressing the CD300c antigen or CD300c receptor, comprising the immune cell described in the above as an active ingredient. <12> The cancer is at least one selected from the group consisting of colorectal cancer, rectal cancer, colon cancer, thyroid cancer, oral cancer, pharyngeal cancer, laryngeal cancer, cervical cancer, brain cancer, lung cancer, ovarian cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, prostate cancer, skin cancer, tongue cancer, breast cancer, uterine cancer, stomach cancer, bone cancer, and blood cancer. <11> 2. The pharmaceutical composition according to claim 1 . <13> The pharmaceutical composition further comprises another anticancer drug. <11> 2. The pharmaceutical composition according to claim 1 . <14> The pharmaceutical composition is characterized in that it inhibits cancer proliferation, survival, metastasis, recurrence, or anticancer drug resistance. <11> 2. The pharmaceutical composition according to claim 1 . <15> <9> A method for preventing or treating cancer, comprising the step of administering to an individual a composition comprising the immune cell described in claim 1 as an active ingredient. <16> <9> 2. Use of a composition comprising the immune cell described in claim 1 as an active ingredient for preventing or treating cancer.

Claims

1. A chimeric antigen receptor that specifically binds to the CD300c antigen, The chimeric antigen receptor comprises six complementarity determining region (CDR) sequences contained in any one of the amino acid sequences selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12; A chimeric antigen receptor comprising an antibody or a single chain variable fragment (scFv).

2. The chimeric antigen receptor according to claim 1, characterized in that the chimeric antigen receptor comprises six complementarity determining region (CDR) sequences contained in the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO:

6.

3. The chimeric antigen receptor according to claim 1, further comprising a signal peptide, a GS linker, a transmembrane domain, and an intracytoplasmic domain.

4. The chimeric antigen receptor of claim 3, wherein the signal peptide is a CD8α signal peptide.

5. The chimeric antigen receptor according to claim 3, wherein the transmembrane domain is a CD8 hinge (hinge of cluster of differentiation 8) and a CD28 transmembrane domain (CD28 transmembrane domain).

6. The chimeric antigen receptor according to claim 3, wherein the intracytoplasmic domain is a CD28 intracellular domain and a CD3ζ intracellular domain.

7. The chimeric antigen receptor according to claim 1, which is used in the treatment of cancer expressing CD300c antigen.

8. A recombinant vector expressing the chimeric antigen receptor according to any one of claims 1 to 7.

9. An immune cell comprising the chimeric antigen receptor according to any one of claims 1 to 7.

10. The immune cells include monocytes, macrophages, T cells, and natural killer cells. The immune cell according to claim 9 , which is at least one selected from the group consisting of a NK cell (killer cell) and a dendritic cell.

11. A pharmaceutical composition for preventing or treating cancer expressing the CD300c antigen, comprising the immune cell described in claim 9 as an active ingredient.

12. The pharmaceutical composition according to claim 11, wherein the cancer is any one or more selected from the group consisting of colorectal cancer, rectal cancer, colon cancer, thyroid cancer, oral cancer, pharyngeal cancer, laryngeal cancer, cervical cancer, brain cancer, lung cancer, ovarian cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, prostate cancer, skin cancer, tongue cancer, breast cancer, uterine cancer, stomach cancer, bone cancer and blood cancer.

13. The pharmaceutical composition according to claim 11, further comprising another anti-cancer drug.

14. The pharmaceutical composition according to claim 11, characterized in that the pharmaceutical composition suppresses cancer proliferation, survival, metastasis, recurrence or anticancer drug resistance.

15. A method for preventing or treating cancer, comprising the step of administering a composition comprising the immune cell according to claim 9 as an active ingredient to an individual other than a human.

16. Use of a composition comprising the immune cell according to claim 9 as an active ingredient in the manufacture of a medicament for preventing or treating cancer.

Citation Information

Patent Citations

  • Treatment of cancer using chimeric antigen receptors

    JP2017513818A

Cited By

  • A chimeric antigen receptor that specifically binds to the CD300c antigen or its receptor

    JP2024522279A

  • Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof

    US12616734B2